Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Hormel Foods Refines Portfolio, Completes CytoSport Sale

Published 04/15/2019, 09:01 PM
Updated 07/09/2023, 06:31 AM

Hormel Foods Corporation (NYSE:HRL) completes the divestiture of CytoSport business to PepsiCo, Inc. (NASDAQ:PEP) . The deal, announced in Feb, 2019, was valued at almost $465 million. Let’s take a closer look.

Is CytoSport Sale a Prudent Move?

As a result of this transaction, renowned brands such as Evolve and Muscle Milk no longer form part of Hormel Foods’ business. We note that management had earlier announced that the performance of CytoSport business was unimpressive during fiscal 2018. Declines in the single serve ready-to-drink product lines and powder products had impaired growth of the category. Intense competition and inadequate distribution were other deterrents. These adversities might have led the company to divest the business. Such efforts are likely to enable the company to focus on other areas with substantial growth potential.

Further, management expects that Pepsi’s strong expertise in the beverages space makes it an appropriate option to include CytoSport business brands. Moreover, Pepsi has been the distribution partner for Muscle Milk for long and holds substantial experience in marketing products in the sports nutrition category. These factors are likely to boost the CytoSport business.

Hormel Foods has not made statements of the divestitures’ material impact on the top line in fiscal 2019.

Wrapping Up

Hormel Foods has undertaken business divestitures in the past as well. The company sold the Fremont processing facility to WholeStone Farms in December 2018. Tough dynamics in the pork industry have compelled the company to resort to the divestiture. In fact, higher tariffs have weighed on fresh pork export volumes, sales and profits at Hormel Foods’ International division. Such headwinds combined with weakness in the turkey segment are impacting investors’ sentiments, evident from the stock’s 4.7% decline in the past three months, against the industry’s rise of 9.5%.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .



Nevertheless, this Zacks Rank #3 (Hold) company focuses on making strategic advertisement investments to support growth of brands and launch products that are in line with consumers’ preferences. Moreover, the company resorts to prudent buyouts. To this end, the Columbus and Fontanini buyouts are driving performance in the Refrigerated Foods segment. Also, the Ceratti acquisition is supporting growth in the International segment.

We expect these factors, combined with management’s efforts to refine the portfolio, to cushion the aforementioned hurdles and boost investors’ sentiments in the forthcoming periods.

Looking For Consumer Staples Stocks? Check These

MEDIFAST (NYSE:MED) , with long-term earnings growth rate of 20%, sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

General Mills (NYSE:GIS) , with a Zacks Rank #2 (Buy), has long-term earnings per share (EPS) growth rate of 7.5%.

Will you retire a millionaire?

One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.

Click to get it free >>



Pepsico, Inc. (PEP): Free Stock Analysis Report

Hormel Foods Corporation (HRL): Free Stock Analysis Report

General Mills, Inc. (GIS): Free Stock Analysis Report

MEDIFAST INC (MED): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.